Skip to content

ABOUT

C2i Genomics

Our ultrasensitive test makes cancer more predictable and manageable

Rapidly transitioning from academia to helping millions

C2i was formally founded in 2019 and is based on technology developed at Cornell and the New York Genome Center. We are backed by top tier VCs. 

Our Company is headquartered in the US with an R&D center in Israel. We brought together outstanding professionals with multidisciplinary expertise in oncology, signal processing, bioinformatics and machine learning.

EXPERTS IN GENOMICS, MEDICINE, AND BUSINESS​

Dr. Asaf Zviran

CEO & CSO

Asaf Zviran, Ph.D

CEO & CSO

Asaf brings 15+ years of R&D management in biology and defense.To date he has managed to publish 13 papers with over 1,700 citations (including Nature and Stem Cell). Asaf received multiple awards and grants. He is an IDF R&D Officer (Captain) with a PhD in Molecular Biology